A Study to Evaluate Efficacy and Safety of CS-3150 in Patients With Severe Hypertension (Grade III)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223232

Enrollment

Registered

2016-06-06

Start date

2016-06-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe hypertension (Grade III)

Interventions

investigational material(s) Generic name etc : CS-3150 INN of investigational material : Esaxerenone Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investigational mat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Male and female subjects aged 20 to 80 years at informed consent 2) Subjects with hypertension, who do not receive any antihypertensive drugs or receive antihypertensive drugs (except for potassium-sparing diuretics) during run-in period (Sitting SBP >= 180 mmHg or Sitting DBP >= 110 mmHg)

Exclusion criteria

Exclusion criteria: 1)Suspected Hypertensive emergency 2)Secondary hypertension or malignant hypertension 3)Diabetic nephropathy 4)Serum potassium level = 5.1 mEq/L (= 4.8 mEq/L if receive RA inhibitor) 5)eGFR < 60 mL/min/1.73 m^2.

Design outcomes

Primary

Measure	Time frame
safety efficacy - Change from baseline in sitting systolic and diastolic blood pressure - Adverse events	—

Secondary

Measure	Time frame
efficacy Time course of sitting systolic and diastolic blood pressure Proportion of patients achieving sitting blood pressure control	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026